Wednesday, December 1, 2021 Daily Archives

Adenovirus Vector Manufacturing Platform Using CIMmultus QA

by

This webcast features: Hana Jug, Project Manager in Process Development for Viral Vectors and Vaccines, BIA Separations Downstream processing remains one of the main bottlenecks in Adenoviral vector manufacturing. At BIA Separations, a Sartorius company, we offer a platform for purification of Adenoviral vaccines using market leading CIM® monolithic chromatographic columns and an analytical toolbox for process monitoring in Adenoviral vaccine production. Simplified purification of Adenovirus consists of typical downstream steps, including combined lysis, clarification, TFF and a chromatographic capture…

December 1, 2021

Sanofi boosts vaccine pipeline with Origimm buy

by

Sanofi will add a potential acne vaccine candidate to its pipeline through the acquisition of Origimm Biotechnology. Sanofi is set to acquire Austrian biotechnology firm Origimm, which specializes in the discovery of virulent skin microbiome components and antigens causing skin diseases for an undisclosed fee. The move sees the French pharma giant  add a potential first-in-class vaccine candidate ORI-001 to treat acne vulgaris, a stigmatizing skin condition that affects millions of people of different ages worldwide. ORI-001 is a therapeutic…

December 1, 2021

Regeneron moving fast to assess Ab cocktail for Omicron variant

by

Regeneron says it can adapt its COVID-19 antibody cocktail to be effective against the Omicron variant if necessary, thanks to lessons learned the first time around. Omicron was the word of the day at the Evercore ISI HealthCONx Conference yesterday, as drug companies assess the potential impact of the recently discovered variant. One company that spoke about its efforts against the new strain was Regeneron, which has been at the forefront of therapeutic development against COVID-19 with its antibody cocktail…

December 1, 2021

Global microbial capacity to reach 575kL by 2025

by

Microbial manufacturing capacity will see steady growth over the next few years as molecular pipelines become more heterogenous, say experts. According to biotechnology group BDO’s Fall 2021 bioTRAK report covering the supply and demand of manufacturing capacity for recombinant biopharmaceuticals, current microbial manufacturing capacity totals more than 500kL. There are over 90 companies actively producing products for the global marketplace from 112 manufacturing plants, Dawn Ecker, managing director, bioTRAK Database Services told us. And “looking forward to 2025, microbial capacity…

December 1, 2021